Genetic screening was performed and confirmed the diagnosis of CPVT, revealing a new heterozygous point mutation in the gene for ryanodine receptor type 2, which, to the best of our knowledge, has not been described to date in the literature. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.